- Ariad Pharmaceuticals (ARIA) collapses 59% after the company says that it's suspending the enrollment of new patients in trials for its Iclusig treatment for chronic myeloid leukemia.
- The pause follows an increase in the rate of cardiac problems in patients who received Iclusig.
- Pending FDA approval, Ariad hopes to resume enrollment with lower doses of the drug. Patients already on the medicine will continue to do so but with smaller doses.
- The U.S. prescribing information for Iclusig remains unchanged. (PR)
Ariad shares plunge after it pauses enrollment for leukemia drug trial
Oct 9 2013, 07:40 ET